Systemic Lupus Erythematosus Decrease

Steroid sparing with novel agents, including belimumab and voclosporin, is recommended for patients with systemic lupus erythematosus, according to updated guidelines presented at the EULAR 2023 Congress.

Treating patients with lupus can be likened to fighting a war, in which victory is achieved not through a single promising therapy, but winning many smaller battles, according to a speaker at EULAR 2023 Congress.

The recent success of chimeric antigen receptor-T cell therapy, along with three high-profile FDA approvals, may help make precision medicine a reality in lupus, according to a presenter at the Biologic Therapies Summit.

The Lupus Research Alliance, alongside its research affiliate Lupus Therapeutics, have announced the launch of what would be the largest prospective observational study into lupus, as well as a new patient registry and data resource.

In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.

Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more likely to die or experience heart failure vs. patients without immune-mediated inflammatory disease, according to data.

PHILADELPHIA — Belimumab demonstrated a strong clinical response and significantly reduced flare risk for patients with cutaneous lupus erythematosus, with or without systemic lupus erythematosus, after 20 weeks, said a presenter here.